1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. GBM Market Overview at a Glance

6.1. Market Share (%) Distribution of GBM by Therapies in 2020

6.2. Market Share (%) Distribution of GBM by Therapies in 2034

7. Disease Background and Overview: GBM

7.1. Introduction

7.2. Classification of GBM

7.3. Glioblastoma Types

7.3.1. Astrocytomas

7.3.2. Ependymomas

7.3.3. Oligodendrogliomas

7.3.4. Mixed gliomas

7.3.5. Optic pathway gliomas

7.4. Symptoms

7.5. Causes

7.6. Pathophysiology

7.6.1. Macroscopic and Histological Features of GBM

7.6.2. Genetic and Molecular Pathogenesis

7.7. Inheritance of GBM

7.7.1. Genetic Variations of GBM

7.7.2. Isocitrate dehydrogenase mutations

7.7.3. O (6)-Methylguanine-DNA methyltransferase promoter methylation

7.7.4. Telomerase reverse transcriptase promoter mutations

7.7.5. Epidermal growth factor receptor aberrations

7.7.6. PTEN alterations

7.7.7. Other novel genetic aberrations

7.8. Molecular Classification

7.8.1. Specific Molecular Biomarkers

7.9. Diagnosis

8. Treatment and Management

8.1. Treatment Guidelines

8.1.1. NCCN Guidelines for Central Nervous System Cancers (Glioblastoma) (2024)

8.1.2. ESTRO-EANO Guideline on Target Delineation and Radiotherapy Details for Glioblastoma (2023)

8.1.3. Guidelines for the Management of Newly Diagnosed GBM (National Institute for Health and Care Excellence [NICE], 2021)

8.1.4. Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021)

8.1.5. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions (2020)

8.1.6. Guidelines for the Treatment of Adult GBM (Japanese Society of Neurological Surgery, 2019)

8.1.7. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of GBM (2018)

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale

9.3. Total Incident Cases of GBM in the 7MM

9.4. The US

9.4.1. Total Incident Cases of GBM in the US

9.4.2. Gender-specific Incident Cases of GBM in the US

9.4.3. Type-specific Incident Cases of GBM in the US

9.4.4. Incident Cases based on Primary Site of GBM in the US

9.4.5. Age-specific Incident Cases of GBM in the US

9.4.6. Incident Cases based on Histologic Classification of GBM in the US

9.4.7. Unmethylation of the MGMT Gene Promoter Cases in the US

9.4.8. BRAF V600E Mutation Cases in GBM in the US

9.4.9. Line-wise Treated Pool of GBM in the US

9.5. EU4 and the UK

9.5.1. Total Incident Cases of GBM in EU4 and the UK

9.5.2. Gender-specific Incident Cases of GBM in EU4 and the UK

9.5.3. Type-specific Incident Cases of GBM in EU4 and the UK

9.5.4. Incident Cases based on Primary Site of GBM in EU4 and the UK

9.5.5. Age-specific Incident Cases of GBM in EU4 and the UK

9.5.6. Incident Cases based on Histologic Classification of GBM in EU4 and the UK

9.5.7. Unmethylation of the MGMT Gene Promoter Cases in EU4 and the UK

9.5.8. BRAF V600E Mutation Cases in GBM in EU4 and the UK

9.5.9. Line-wise Treated Pool of GBM in EU4 and the UK

9.6. Japan

9.6.1. Total Incident Cases of GBM in Japan

9.6.2. Gender-specific Incident Cases of GBM in Japan

9.6.3. Type-specific Incident Cases of GBM in Japan

9.6.4. Incident Cases based on Primary Site of GBM in Japan

9.6.5. Age-specific Incident Cases of GBM in Japan

9.6.6. Incident Cases based on Histologic Classification of GBM in Japan

9.6.7. Unmethylation of the MGMT Gene Promoter Cases in Japan

9.6.8. BRAF V600E Mutation Cases in GBM in Japan

9.6.9. Line-wise Treated Pool of GBM in Japan

10. Patient Journey

11. Key Endpoints

12. Marketed Drugs

12.1. Key Competitors

12.2. AVASTIN (bevacizumab): Roche (Genentech)

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activities

12.2.4. Safety and Efficacy

12.3. TEMODAR/TEMODAL (temozolomide): Merck

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.4. Safety and Efficacy

12.4. DELYTACT (teserpaturev/G47?): Daiichi Sankyo

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Safety and Efficacy

12.5. TAFINLAR/FINLEE (dabrafenib) + MEKINIST (trametinib): Novartis

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activities

12.5.4. Safety and Efficacy

12.6. OPTUNE GIO: Novocure

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Other Developmental Activities

12.6.4. Clinical Development

12.6.5. Safety and Efficacy

12.7. STIVARGA (regorafenib): Bayer

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Other developmental activities

12.7.4. Clinical development

12.7.5. Safety and Efficacy

13. Emerging Drugs

13.1. Key Competitors

13.2. AV-GBM-1: Aivita Biomedical and TAE Life Sciences

13.2.1. Product Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.3. DB107 (vocimagene amiretrorepvec-flucytosine): Denovo Biopharma

13.3.1. Product Description

13.3.2. Other Development Activities

13.3.3. Clinical Development

13.4. DCVax-L: Northwest Biotherapeutics and Advent BioServices

13.4.1. Product Description

13.4.2. Other Developmental Activities

13.4.3. Clinical Development

13.4.4. Safety and Efficacy

13.5. Eflornithine: Orbus Therapeutics

13.5.1. Product Description

13.5.2. Other Developmental Activities

13.5.3. Clinical Development

13.6. TVI-Brain-1: TVAX Biomedical

13.6.1. Product Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.7. LAM561 (2-OHOA): Laminar Pharmaceuticals

13.7.1. Product Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Safety and Efficacy

13.8. VT1021: Vigeo Therapeutics

13.8.1. Product Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.4. Safety and Efficacy

13.9. VERZENIO (abemaciclib, LY2835219): Eli Lilly and Company

13.9.1. Product Description

13.9.2. Other Development Activities

13.9.3. Clinical Development

13.9.4. Safety and Efficacy

13.10. PEMAZYRE (pemigatinib): Incyte Corporation

13.10.1. Product Description

13.10.2. Other Development Activities

13.10.3. Clinical Development

13.11. Paxalisib (GDC-0084): Kazia Therapeutics

13.11.1. Product Description

13.11.2. Other Developmental Activities

13.11.3. Clinical Development

13.11.4. Safety and Efficacy

13.12. BMX-001: BioMimetix

13.12.1. Product Description

13.12.2. Other Developmental Activities

13.12.3. Clinical Development

13.12.4. Safety and Efficacy

13.13. Bizaxofusp (MDNA55): Medicenna Therapeutics

13.13.1. Product Description

13.13.2. Other Developmental Activities

13.13.3. Clinical Development

13.13.4. Safety and Efficacy

13.14. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

13.14.1. Product Description

13.14.2. Other Developmental Activities

13.14.3. Clinical Development

13.14.4. Safety and Efficacy

13.15. SurVaxM: MimiVax

13.15.1. Product Description

13.15.2. Other Developmental Activities

13.15.3. Clinical Development

13.15.4. Safety and Efficacy

13.16. OKN-007: Oblato

13.16.1. Product Description

13.16.2. Other developmental Activities

13.16.3. Clinical Development

13.16.4. Safety and efficacy

13.17. Berubicin: CNS Pharmaceuticals

13.17.1. Product Description

13.17.2. Other Developmental Activities

13.17.3. Clinical Development

13.17.4. Safety and Efficacy

13.18. IGV-001: Imvax

13.18.1. Product Description

13.18.2. Other Developmental Activities

13.18.3. Clinical Development

13.18.4. Safety and efficacy

13.19. BGB-290 (pamiparib): Beigene

13.19.1. Product Description

13.19.2. Clinical Development

13.19.3. Safety and Efficacy

13.20. EO2401: Enterome

13.20.1. Product Description

13.20.2. Other Developmental Activities

13.20.3. Clinical Development

13.20.4. Safety and Efficacy

13.21. VBI-1901: VBI Vaccines

13.21.1. Product Description

13.21.2. Other Developmental Activities

13.21.3. Clinical Development

13.21.4. Safety and Efficacy

13.22. Temferon: Genenta Science

13.22.1. Product Description

13.22.2. Other Development Activities

13.22.3. Clinical Development

13.22.4. Safety and Efficacy

13.23. NOX-A12 (olaptesed pegol): TME Pharma

13.23.1. Product Description

13.23.2. Other Developmental Activities

13.23.3. Clinical Development

13.23.4. Safety and Efficacy

13.24. INO-5401 + INO-9012 + LIBTAYO (cemiplimab): Inovio Pharmaceuticals and Regeneron Pharmaceuticals

13.24.1. Product Description

13.24.2. Other Developmental Activities

13.24.3. Clinical Development

13.24.4. Safety and Efficacy

13.25. Lerapolturev: Istari Oncology and FUJIFILM Diosynth Biotechnologies

13.25.1. Product Description

13.25.2. Other Developmental Activities

13.25.3. Clinical Development

13.25.4. Safety and Efficacy

13.26. Rhenium (186Re) obisbemeda: Plus Therapeutics

13.26.1. Product Description

13.26.2. Other Developmental Activities

13.26.3. Clinical Development

13.26.4. Safety and Efficacy

14. GBM: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Outlook

14.3. Key Market Forecast Assumptions

14.3.1. Cost Assumptions and Rebates

14.3.2. Pricing Trends

14.3.3. Analogue Assessment

14.3.4. Launch Year and Therapy Uptake

14.4. Conjoint Analysis

14.5. Total Market Size of GBM in the 7MM

14.6. The US Market Size

14.6.1. Total Market Size of GBM in the US

14.6.2. Market Size of GBM by Therapies in the US

14.7. EU4 and the UK Market Size

14.7.1. Total Market Size of GBM in EU4 and the UK

14.7.2. Market Size of GBM by Therapies in EU4 and the UK

14.8. Japan Market Size

14.8.1. Total Market Size of GBM in Japan

14.8.2. Market Size of GBM by Therapies in Japan

15. Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

18.1. United States

18.1.1. Centre for Medicare and Medicaid Services (CMS)

18.2. EU4 and the UK

18.2.1. Germany

18.2.2. France

18.2.3. Italy

18.2.4. Spain

18.2.5. United Kingdom

18.3. Japan

18.3.1. MHLW

18.4. Market Access and Reimbursement of GBM

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DRA Reports Capabilities

21. Disclaimer

22. About DRA Reports